海通证券股份有限公司关于上海毕得医药科技股份有限公司 2023 年度持续督导现场检查报告 上海证券交易所： 经中国证券监督管理委员会《关于同意上海毕得医药科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2022〕1885 号）核准，上海毕得医药 科技股份有限公司（以下简称"毕得医药"、"上市公司"、"公司"）首次公开发 行股票，每股面值人民币 1 元，每股发行价格人民币 88.00 元，募集资金总额为 人民币 1,428,160,800.00 元，扣除发行费用后，实际募集资金净额为人民币 1,308,998,865.06 元。本次发行证券已于 2022 年 10 月 11 日在上海证券交易所上 市。海通证券股份有限公司（以下简称"海通证券"、"保荐机构"）担任其持续 督导保荐机构，持续督导期间为 2022 年 10 月 11 日至 2025 年 12 月 31 日。 根据《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票上市 规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等 有关法律、法规要求，海通证券作为持续督导保荐机构，于 2024 年 4 月 18 日至 20 ...

海通证券股份有限公司关于上海毕得医药科技股份有限公司 2023 年度持续督导年度跟踪报告 | 保荐机构名称：海通证券股份有限公司 | 被保荐公司简称：毕得医药 | | --- | --- | | 保荐代表人姓名：雷浩、李华东 | 被保荐公司代码：688073.SH | 经中国证券监督管理委员会《关于同意上海毕得医药科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]1885 号）核准，上海毕得医药科技 股份有限公司（以下简称"毕得医药、""上市公司"、"公司"或"发行人"） 首次公开发行股票 1,622.9100 万股，每股面值人民币 1 元，每股发行价格人民币 88.00 元，募集资金总额为人民币 142,816.08 万元，扣除相关发行费用后，实际 募集资金净额为人民币 130,899.89 万元。本次发行证券已于 2022 年 10 月 11 日 在上海证券交易所上市。海通证券股份有限公司（以下简称"保荐机构"或"海 通证券"）担任其持续督导保荐机构，持续督导期间为 2022 年 10 月 11 日至 2025 年 12 月 31 日。 在 2022 年 10 月 11 日至 2025 ...

证券代码：688073 证券简称：毕得医药 公告编号：2024-019 上海毕得医药科技股份有限公司 关于以集中竞价交易方式回购股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2023/12/9 | | --- | --- | | 回购方案实施期限 | 待第二届董事会第五次会议审议通 | | | 过后 12 个月 | | 预计回购金额 | 5,000 万元~10,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 2,129,043 股 | | 累计已回购股数占总股本比例 | 2.3426% | | 累计已回购金额 | 8,742.02 万元 | | 实际回购价格区间 | 31.01 元/股~52.99 元/股 | 一、 回购股份的基本情况 2023 年 12 月 8 日，公司召开第二届董事会第五次会议、第二 届监事会第五次会议，审议通过了《关于以 ...

Financial Performance - In Q1 2024, the company achieved operating revenue of CNY 263 million, a year-on-year increase of 4.05% [1] - The net profit attributable to shareholders was CNY 26.07 million, with a quarter-on-quarter increase of CNY 29.90 million [1] - The non-recurring net profit was CNY 25.43 million, up CNY 10.41 million quarter-on-quarter [1] - Operating cash flow was CNY 48.17 million, turning from negative to positive, with a year-on-year increase of CNY 69.63 million [2] Market and Customer Insights - In Q1 2024, overseas revenue reached CNY 148 million, indicating potential for further growth [2] - The number of active domestic customers increased to over 3,800, a year-on-year growth of 13.25% [2] - The number of publications using the company's products reached over 2,600 in 2023, with a significant increase in the number of publications to over 5,100 [2] Dividend and Profit Distribution - For the fiscal year 2023, the company reported a net profit of CNY 109.57 million, with an unallocated profit of CNY 150.68 million as of year-end [3] - The proposed cash dividend is CNY 0.90 per share (before tax), with a total cash dividend amounting to CNY 79.88 million, representing 72.90% of the annual net profit [3] Future Strategies - The company plans to enhance management efficiency by optimizing inventory and processes to reduce costs and improve net profit margins [2] - Future product development will focus on expanding product lines and improving synthesis processes, with an emphasis on customer needs [4] - The company aims to strengthen its global presence by establishing regional centers in key drug development areas and increasing business development personnel in overseas markets [5] Share Buyback and Employee Incentives - As of the report date, the company has repurchased 2,129,043 shares, accounting for 2.34% of the total share capital [4] - The management is currently discussing incentive plans for employees, with future disclosures planned as per legal requirements [4]

Investment Rating - The investment rating for the company is "Buy" [8]. Core Views - The report indicates that the company has shown a strong revenue growth of 31% in reagent income and 47% in molecular block income, with total revenue expected to reach approximately 1.46 billion in 2023 [8]. - The company has successfully expanded its market presence, particularly in the overseas market, with a notable increase in product penetration [8]. - The report highlights improvements in operational efficiency following management changes, with a significant increase in the number of available products and stable cash flow [8]. Financial Summary - Total revenue is projected to grow from 834 million in 2022 to 1,823 million by 2026, with year-on-year growth rates of 37.5%, 30.9%, 20.8%, 18.8%, and 16.4% respectively [8]. - Net profit attributable to the parent company is expected to increase from 146 million in 2022 to 198 million by 2026, with growth rates of 49.6%, -24.9%, 20.2%, 25.6%, and 19.6% [8]. - The gross margin is projected to decline slightly from 44.4% in 2022 to 37.3% in 2026 [8]. - Return on equity (ROE) is expected to improve from 7.0% in 2022 to 7.7% in 2026 [8]. - Earnings per share (EPS) is forecasted to rise from 1.98 in 2023 to 2.18 in 2026, with corresponding price-to-earnings (P/E) ratios decreasing from 41.49 to 15.35 [8].

Financial Performance - The company's revenue for Q1 2024 was CNY 262,669,977.50, representing a year-over-year increase of 4.05%[5] - Net profit attributable to shareholders decreased by 29.39% to CNY 26,074,943.00 compared to the same period last year[5] - The basic and diluted earnings per share were both CNY 0.29, reflecting a decline of 29.27% year-over-year[5] - Total operating revenue for Q1 2024 was CNY 262,669,977.50, an increase of 4.87% compared to CNY 252,455,900.29 in Q1 2023[18] - Net profit for Q1 2024 was CNY 26,074,943.00, a decrease of 29.3% from CNY 36,928,240.19 in Q1 2023[19] - Earnings per share for Q1 2024 was CNY 0.29, down from CNY 0.41 in Q1 2023[19] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,381,919,508.50, a decrease of 1.37% from the end of the previous year[6] - Total assets as of Q1 2024 amounted to CNY 2,381,919,508.50, a slight decrease from CNY 2,415,027,980.82 at the end of the previous period[16] - Total liabilities for Q1 2024 were CNY 336,679,198.66, compared to CNY 325,485,828.49 in the previous period, reflecting an increase of 4.0%[16] - Total non-current assets decreased to CNY 142,171,264.41 from CNY 153,861,833.35, indicating a decline of 7.6%[16] Equity and Shareholder Information - The total equity attributable to shareholders decreased by 2.12% to CNY 2,045,240,309.84 compared to the end of the previous year[6] - The company’s total equity decreased to CNY 2,045,240,309.84 from CNY 2,089,542,152.33, reflecting a decline of 2.12%[16] - Total number of common shareholders at the end of the reporting period was 4,933[11] - The top 10 shareholders collectively hold 47.03% of the company's shares, with the largest shareholder being Dai Lan, holding 32.6%[12] - The company has a share repurchase account holding 2,129,043 shares, representing 2.34% of total shares[12] - The company is actively managing its shareholder relationships, with no reported related party transactions among other shareholders[12] Cash Flow - The net cash flow from operating activities was CNY 48,167,499.32, with no comparative data available[5] - Cash inflow from operating activities for Q1 2024 was $283.64 million, an increase of 3.0% compared to $274.83 million in Q1 2023[21] - Net cash flow from operating activities for Q1 2024 was $48.17 million, a significant recovery from a net outflow of $21.46 million in Q1 2023[21] - Cash outflow for purchasing goods and services decreased to $162.27 million in Q1 2024 from $238.12 million in Q1 2023, representing a reduction of 31.8%[21] - Cash inflow from investment activities was $1.36 million in Q1 2024, down from $3.47 million in Q1 2023, indicating a decline of 60.8%[22] - Net cash flow from investment activities was -$0.95 million in Q1 2024, an improvement from -$7.00 million in Q1 2023[22] - Cash inflow from financing activities increased significantly to $39.75 million in Q1 2024 from $0.19 million in Q1 2023[22] - Net cash flow from financing activities was -$37.13 million in Q1 2024, worsening from -$3.05 million in Q1 2023[22] - The ending cash and cash equivalents balance for Q1 2024 was $1.27 billion, compared to $1.46 billion at the end of Q1 2023[22] - The company experienced a foreign exchange impact of -$0.92 million on cash and cash equivalents in Q1 2024, compared to -$0.17 million in Q1 2023[22] Expenses and Costs - Research and development expenses totaled CNY 15,420,297.35, accounting for 5.87% of revenue, down 0.53 percentage points from the previous year[6] - The company experienced a decline in net profit primarily due to the growth rate of costs and expenses exceeding that of revenue[9] - Total operating costs for Q1 2024 were CNY 225,411,993.32, up 10.83% from CNY 203,401,460.75 in Q1 2023[18] - The company reported a financial expense of CNY -7,645,483.44 in Q1 2024, compared to CNY -2,676,576.18 in Q1 2023, showing an increase in financial costs[18] Other Information - The company is focused on expanding its market presence and developing new products and technologies[11] - The company reported cash and cash equivalents of approximately ¥1.28 billion, an increase from ¥1.27 billion at the end of 2023[14] - Total current assets amounted to approximately ¥2.24 billion, a slight decrease from ¥2.26 billion in the previous period[14] - Inventory decreased to approximately ¥670.41 million from ¥699.43 million[14] - The company’s deferred income tax assets were CNY 18,841,531.42, slightly up from CNY 18,360,441.47 in the previous period[16] - The company did not adopt new accounting standards for the first quarter of 2024[23]

上海毕得医药科技股份有限公司 年度募集资金存放与使用情况鉴证报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 目 录 | 二、上海毕得医药科技股份有限公司关于 2023 年度募集资金 | | | --- | --- | | 一、年度募集资金存放与使用情况鉴证报告 存放与使用情况的专项报告 | 页 次 1-2 3-9 | 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 Floors 5–8, 12 and 23, Block A, UDC Times Building, No. 8 Xinye Road, Qianjiang New City, Hangzhou Tel. 0571-88879999 Fax. 0571-88879000 www.zhcpa.cn 年 ...

Financial Performance - In 2023, the company achieved a net profit attributable to shareholders of RMB 109,571,788.68, with an undistributed profit of RMB 150,677,721.62 at year-end[6]. - The proposed cash dividend is RMB 9 per 10 shares, resulting in a total cash dividend distribution of RMB 79,878,515, which represents 72.90% of the annual net profit attributable to shareholders[6]. - The company's operating revenue for 2023 reached ¥1,091,858,561.97, representing a 30.94% increase compared to ¥833,831,622.63 in 2022[22]. - The net profit attributable to shareholders decreased by 24.94% to ¥109,571,788.68 from ¥145,970,727.07 in the previous year[22]. - The net cash flow from operating activities was negative at -¥57,387,600.78, a decline of 292.12% compared to ¥29,871,071.18 in 2022[22]. - The company's gross profit margin decreased from 44.38% in 2022 to 40.00% in the reporting period, indicating a continuous decline[86]. - The company reported a total revenue of 8,170 million RMB for the year, with a year-on-year increase of 52.5% from 5,382.86 million RMB[75]. - The company achieved a total revenue of RMB 1,091,858,561.97 in the reporting period, representing a year-on-year growth of 30.94%[90]. Research and Development - The company remains focused on research and development of new products and technologies, although specific details are not provided in the extracted content[12]. - Research and development expenses accounted for 5.79% of operating revenue, an increase of 0.26 percentage points year-on-year[24]. - The company has developed multiple new types of molecular building blocks, optimizing cyclization preparation reactions to expand application ranges[75]. - Total R&D investment for the year reached ¥63,227,409.30, a 37.23% increase from the previous year, with R&D expenses accounting for 5.79% of total revenue[61]. - The company is enhancing its research capabilities in modern organic chemistry and materials science to support new product development[71]. - The company is currently developing KRAS G12C inhibitors with a focus on boronic acid building blocks, aiming to enhance synthesis methods and production scalability[72]. - The ongoing research on RAR agonists involves optimizing boronic acid building blocks to improve their properties for client selection[73]. Market Expansion and Strategy - The company plans to enhance its warehouse capabilities in the U.S. with intelligent layout to strengthen its global competitive position[36]. - The company aims to enhance its global presence by establishing regional centers in key new drug research areas and increasing business development efforts in overseas markets[124]. - The company is exploring new strategies for market expansion and product development in the field of advanced organic chemistry[65]. - The company plans to continue expanding its global market presence and enhance customer support capabilities[82]. - The company is focusing on expanding its market presence through innovative drug development and advanced materials technology[66]. - The company plans to build a digital system to enhance data connectivity across various business processes, aiming for high-quality growth in the long term[126]. Corporate Governance and Compliance - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has received a standard unqualified audit report from Zhonghui Certified Public Accountants[5]. - The board of directors and management have confirmed the authenticity, accuracy, and completeness of the annual report[4]. - The company has established a governance structure that complies with relevant laws and regulations, ensuring effective internal control[184]. - The company emphasizes the importance of ESG (Environmental, Social, and Governance) strategies and has integrated them into its overall business strategy[185]. - The company maintains a structured governance framework to protect the rights of shareholders and creditors[200]. Risk Management - The company has outlined various risks and countermeasures in the report, emphasizing the importance of investor awareness regarding investment risks[4]. - The company maintains a focus on risk management in its foreign exchange hedging activities, adhering to principles of legality, prudence, safety, and effectiveness[120]. Employee and Talent Management - The total number of employees in the parent company and major subsidiaries is 846, with 413 in the parent company and 433 in subsidiaries[166]. - The company organized 67 offline training sessions during the reporting period to enhance employee skills and knowledge[169]. - The average salary for R&D personnel decreased to 24.05 million RMB from 25.61 million RMB, reflecting adjustments in compensation strategy[77]. - The company emphasizes the importance of building a talent pipeline and enhancing corporate culture to support high-quality development[124]. Environmental Responsibility - The company invested 2.79 million yuan in environmental protection during the reporting period[186]. - The company is not classified as a key pollutant discharge unit and has complied with environmental impact assessment requirements[187]. - The company has established an environmental management system compliant with ISO14001:2015 standards[194]. - The company focuses on reducing energy consumption and has implemented measures to manage water and electricity usage effectively[195].

上海毕得医药科技股份有限公司 独立董事张萌 2023 年度述职报告 作为上海毕得医药科技股份有限公司（以下简称"公司"）的独立董事，2023 年本人在任职期间严格按照《上市公司独立董事管理办法》、《上海证券交易所 科创板股票上市规则》、《上市公司治理准则》等相关法律、法规，以及《上海 毕得科技股份有限公司公司章程》（以下简称"《公司章程》"）、《上海毕得 科技股份有限公司独立董事制度》等制度规定，在 2023 年度工作中，尽职尽责 地履行独立董事的职责，积极出席相关会议，认真审议董事会各项议案，从公司 整体利益出发，发挥了独立董事应有的作用，维护了公司和全体股东特别是中小 股东的合法权益。现将本人 2023 年度履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 公司第一届董事会有三名独立董事，分别是本人，魏炜先生，田伟生先生， 独立董事的选任均符合《公司法》等有关法律法规及公司章程要求。本人基本情 况如下： 张萌，男，中国国籍，无境外永久居留权，1971 年出生，硕士研究生学历， 中国注册会计师（非执业），中国注册税务师。1994 年 9 月至 1997 年 3 ...

上海毕得医药科技股份有限公司 独立董事孟鸿 2023 年度述职报告 作为上海毕得医药科技股份有限公司（以下简称"公司"）的独立董事，2023 年本人在任职期间严格按照《上市公司独立董事管理办法》、《上海证券交易所 科创板股票上市规则》、《上市公司治理准则》等相关法律、法规，以及《上海 毕得科技股份有限公司公司章程》（以下简称"《公司章程》"）、《上海毕得 科技股份有限公司独立董事制度》等制度规定，在 2023 年度工作中，尽职尽责 地履行独立董事的职责，积极出席相关会议，认真审议董事会各项议案，从公司 整体利益出发，发挥了独立董事应有的作用，维护了公司和全体股东特别是中小 股东的合法权益。现将本人 2023 年度履行独立董事职责的情况汇报如下： 一、独立董事的基本情况 （一）工作履历、专业背景以及兼职情况 公司第二届董事会有三名独立董事，分别是本人，刘志常先生，陶永平先生， 独立董事的选任均符合《公司法》等有关法律法规及公司章程要求。本人基本情 况如下： 孟鸿，男，中国国籍，无境外永久居留权，1966 年出生，博士研究生学历。 荣获国家"特聘专家"，广东省珠江人才计划"领军人才"，深圳市"海外高层 次人才 A ...